Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fewer CV events, less nephropathy with iodixanol vs iopromide

    • 13 Accesses

    This is a preview of subscription content, log in to check access.


    1. 1.

      GE Healthcare.Study shows GE Healthcare's VisipaqueTM Associated with Lower Incidence of Contrast-Induced Nephropathy and Cardiovascular Events in Patients with Chronic Kidney Disease Compared to Iopromide. Media Release: 22 Nov 2008. Available from: URL: http://www.gehealthcare.com

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Fewer CV events, less nephropathy with iodixanol vs iopromide. React. Wkly. 1230, 2 (2008). https://doi.org/10.2165/00128415-200812300-00004

    Download citation


    • Iodine
    • Chronic Kidney Disease
    • Image Quality
    • Kidney Disease
    • Contrast Agent